Compare Harley-Davidson Inc (HOG) vs TransMedics Group Inc (TMDX) Price & Performance

Harley-Davidson (HOG) trades at $26.75, down 0.74% on the day, with a bullish technical signal from moving averages. Recent earnings show a mixed track record, with a Q2 2026 beat but misses in prior quarters. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though net income remains positive. The stock is valued at a P/E of 14.86 and P/S of 0.72, below industry averages, while analyst sentiment is mixed with a $28.50 consensus target.

The outlook is cautious; while valuation appears attractive and technicals suggest near-term strength, declining revenue and margin pressures pose fundamental risks. Investor sentiment is divided, with institutional activity showing both accumulation and divestment. Key catalysts include execution of the 'Back to the Bricks' strategy, but tariff exposures and competitive threats remain headwinds.

TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.

The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.